From Financial Modeling Prep: 2024-11-08 07:00:01

Xeris Biopharma’s stock has seen an increase in the consensus price target, with Craig-Hallum setting a higher target of $6.5. The company reported a 25% rise in total product sales in the first quarter, driven by Gvoke and Recorlev. Analysts are optimistic about Xeris’ future growth potential in the biopharmaceutical market.



Read more at Financial Modeling Prep:: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Overv…